When giving single agent docetaxel for patients with metastatic NSCLC who have progressed on platinum and immunotherapy, do you stop after 6 cycles or do you continue as long as tolerated and disease is stable?
Answer from: Medical Oncologist at Academic Institution
When giving docetaxel to patients with NSCLC who have disease progression after platinum chemotherapy and immunotherapy, I typically give it in combination with ramucirumab per the REVEL study (Garon et al., PMID 24933332). In this study, patients with NSCLC who had disease progression after platinu...
Comments
Medical Oncologist at University of Minnesota Medical School I agree that continuing treatment until progressio...
I agree that continuing treatment until progressio...